8-2-337, ROAD NO.3 BANJARA HILLS, HYDERABAD, K7
Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
Schedule of Analyst / Institutional Investor Meetings
Allotment of Equity Shares on Exercise of Stock Options Under ESOPs
Intimation Under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings
Files Annual Report in Form 20-F for Fiscal Year Ended March 31, 2026
Company to Participate in Investor Conference on June 5, 2026
To Ring the Closing Bell® at the New York Stock Exchange
Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
No filings found
Initial Statement of Beneficial Ownership
Registration Statement for Depositary Shares
Confidential Treatment Order
Submission Upload
Correspondence